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Poster Session I 41Surgical management can be delayed by pancytopenia or other
complications of PSCT. Transsphenoidal surgery has been shown
to be more successful in improving vision if performed within 8
days of diagnosis. Emergent surgery is indicated for deteriorating
vision, hemiparesis, or altered consciousness, while those with sta-
ble or resolving visual field deficits can be managed conservatively.
Our patient was managed conservatively until engraftment. Trans-
sphenoidal surgery was then performed, 9 days after diagnosis. At
six months follow-up, his visual deficits had resolved but he contin-
ued to have diabetes insipidus.GRAFT PROCESSING105
AUGMENTATION OF STANDARD UMBILICAL CORD BLOOD TRANSPLAN-
TATIONWITH ALDHbr CELLS: RESULTS OF A PHASE I STUDY IN PEDIAT-
RIC PATIENTS
Kurtzberg, J.1, Mendizabal, A.2, Carter, S.2, Reese, M.1, Kaestner, A.1,
Hickerson, D.3, Winstead, L.3, Fiordalisi, M.3, Waters-Pick, B.1,
Balber, A.3 1Duke University Medical Center, Durham, NC; 2The
EMMES Corporation, Rockville, MD; 3Aldagen, Durham, NC.
Transplantation of unrelated donor umbilical cord blood (UCB)
is limited by graft failure and engraftment delays. Strategies to facil-
iate engraftment are needed. Cord blood contains a population
(0.5%) of cells expressing aldehyde dehydrogenase (ALDHbr), an
intracellular enzyme highly enriched in hematopoietic stem and
progenitor cells. The primary endogenous substrates for ALDH
are retinaldehydes, oxidized to retinoic acid, which exert major ef-
fects on hematopoiesis. We hypothesized that augmentation of
a standard UCB transplant with ALDHbr cells isolated from a por-
tion of the graft would improve engraftment. Over the past 2 years,
21 pediatric patients with malignant (n5 7) and metabolic (n5 14)
disorders prepared with myeloablative preparative regimens were
transplantedwith aUCBunit cryopreserved in a compartmentalized
bag allowing for 80% of the unit to be administered as a conven-
tional graft and 20% as purified ALDHbr cells, freshly isolated (n
5 8) or primed with cytokines 5 days (n5 13). Neither infusional
toxicity nor an increase in unexpected adverse events were observed.
The cumulative incidences (CI) of neutrophil (ANC 500 by day 42)
and platelet engraftment (Platelets 50 k by day 180) were 92.9%
(95% CI 73.1–100.0) and 73.1 (95%CI 41.7–100.0). These results
were compared to a control group from the COBLT study, which
contained similar patients (although it was not possible to match
all characteristics between the 2 groups), where the CI of neutrophil
and platelet engraftment were 77.9% (95% CI 67.9–87.9) and
64.9% (95% CI 51.6–78.2). These differences favored patients
transplanted with ALDHbr cells at p5 0.01 and p5 0.02. Neutro-
phil engraftment occurred in a median of 19 versus 26 days in the
ALDH versus COBLT patients. Platelet engraftment was acceler-
ated to 58 days in the ALDH patients compared to 107 days in
the COBLT patients. Significant accelerations in neutrophil and
platelet engraftment were also observed in a subgroup analysis of
metabolic patients alone. There were no differences seen between
groups receiving freshly sorted versus primed ALDHbr cells. While
preliminary, these results suggest that the infusion of ALDHbr cells
facilitates overall engraftment, perhaps through a niche effect. Fur-
ther investigation of mechanisms of action and a phase II study are
underway.106
PHASE 1 TRIAL OF AUTOLOGOUS BONEMARROWMESENCHYMAL STEM
CELL TRANSPLANTATION IN PATIENTS WITH DECOMPENSATED LIVER
CIRRHOSIS
Alimoghaddam, K.1, Mohamadnejad, M.2, Mohyedin Bonab, M.1,
Bagheri, M.2, Bashtar, M.1, Ghanati, H.3, Ghavamzadeh, A.1,
Malekzadeh, R.1 1University of Tehran/Medical Sciences, Tehran, Is-
lamic Republic of Iran; 2Digestive Disease Research Center of University
of Tehran/Medical Sciences, Tehran, Islamic Republic of Iran; 3Univer-
sity of Tehran/Medical Sciences, Tehran, Islamic Republic of Iran.Background: The standard treatment for decompensated liver
cirrhosis is liver transplantation. However, it has several limitations.
Recent animal studies suggest that bone marrow stem cell trans-
plantation can lead to regression of liver fibrosis. The objective of
this study was to determine the safety and feasibility of autologous
bone marrow-mesenchymal stem cell transplantation in patients
with decompensated liver cirrhosis.Methods: In this phase 1 trial,
four patients with decompensated liver cirrhosis were included.
Their bone marrow was aspirated, mesenchymal stem cells were
cultured, and a mean 31.73  106 mesenchymal stem cells were in-
fused through a peripheral vein. Primary outcomes were evaluating
the safety and feasibility of the work. Secondary outcomes were
evaluating changes in the model for end-stage liver disease score,
and the quality of life of the patients. Results: There were no
side-effects in the patients during follow-up. The model for end-
stage liver disease scores of patients 1, and 4 improved by four
and three points, respectively by the end of follow-up. Furthermore,
the quality of life of all four patients improved by the end of follow-
up. Using SF-36 questionnaire, the mean physical component scale
increased from 31.44 to 65.19, and the mean mental component
scale increased from 36.32 to 65.55. Conclusion: Mesenchymal
stem cell transplantation seems to be feasible and safe in the treat-
ment of decompensated liver cirrhosis.107
POST THAW COLONY FORMING UNITS (CFU) IS A STRONG INDEPEN-
DENT PREDICTOR OF ENGRAFTMENT AFTER UNRELATED DONOR UM-
BILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Page, K.M.1, Mendizabal, A.2, Waters-Pick, B.1, Avrutsky, S.1,
Reese, M.1, Prasad, V.K.1, Kurtzberg, J.1 1Duke University Medical
Center, Durham, NC; 2Rockland, MD.
Background: Unrelated donor umbilical cord blood has in-
creased access to transplant for patients lacking matched donors.
However, a non-engraftment rate of approximately 20% despite ad-
equate total nucleated cell (TNC) dose remains a barrier to it’s
overall success. We hypothesized that certain properties of the
UCB graft would be predictive of engraftment.Methods:We per-
formed a retrospective analysis of 423 unrelated donor umbilical
cord blood transplants (UCBT) performed at Duke between 2/
11/2000 and 5/1/2007. Eligible units were required to have pre-
cryopreservation (pre-cryo) data for TNC, CD34 1/- CFU. The
units were obtained from 16 US public cord blood banks and
were selected for transplantation by pre-cryo cell dose and HLA
matching. Pre-cryo data was provided by the cord blood bank as
part of routine banking practices. All units were thawed and washed
in the Duke Stem Cell Laboratory before transplant. Post-thaw
testing (TNC, viability, CD34, CFU) was performed by consistent
personnel. Univariate and multivariate analyses were performed to
identify significant pre-cryo, post-thaw, and baseline factors predic-
tive of neutrophil and platelet engraftment. Results: Patients in the
cohort were characterized as follows: 68% had malignancies, 61%
males, 73% Caucasian and 38% CMV1. Graft/patient mismatch-
ing was present for HLA (93%), sex (50%) and race (24%). There
was excellent correlation between pre-cryo and post-thaw TNC
(r2 5 0.92) and CD34 (r2 5 0.68) content, but much weaker corre-
lation for CFUs (r2 5 0.27). In univariate analysis, pre-cryo/
post-thaw CD34 (larger) and pre-cryo/post-thaw CFU (larger),
pre-cryo/post-thaw TNC (larger), age (#5 years), disease (non-
malignant), weight (#12 kg), CMV status (negative), recipient
ethnicity (Caucasian), HLA match (5/6 or 6/6) were predictive of
neutrophil and platelet engraftment. In the overall multivariate
analysis of neutrophil engraftment, larger post-thaw CFU
(\0.0001), larger post-thaw CD34 (p 5 0.02), Male units (p 5
0.01), 5/6 or 6/6 HLAmatch (p5 0.02) were significant. For plate-
let engraftment, larger post-thaw CFU (p 5 0.002) and Caucasian
recipients (p 5 0.006) were predictive. Conclusions: Post-thaw
CFUs are a strong independent laboratory predictor of neutrophil
and platelet engraftment after UCBT. Efforts should be focused
on developing a reproducible assay on CBU segments that would
correlate with results obtained at thaw of the UCB unit and thus
serve as a potency assay before UCB release from the bank.
